Targeting the SIRT6/Keap1/Nrf2/GPX4 signaling pathway facilitates ferroptosis in cancer cells, and this property may be may be one of the potential strategies to address the resistance of cancer cells to sorafenib. The gene discussed is KEAP1; the disease is cancer.